Clinical Trial Detail

NCT ID NCT02115282
Title Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

breast adenocarcinoma

Therapies

Goserelin

Entinostat

Exemestane

Age Groups: adult

Additional content available in CKB BOOST